While pre-clinical evidence supports a role for HMAs in enhancing the GVL effect, the potential impact of BCL-2 inhibition on the GVL effect is unclear, but the remarkable efficacy of the BCL-2 inhibitor venetoclax in combination with HMAs for newly diagnosed AML in the elderly suggests that this could be a viable strategy for the treatment of post-transplant relapse. Here, BCL2 is linked to acute myeloid leukemia.